Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Presentations

News

News

  • Press Releases
  • Presentations
  • Events
Tuspetinib Clinical Update and KOL Data Review

Tuspetinib Clinical Update and KOL Data Review

Oct 30, 2023
2023 ESH Poster – Tuspetinib Oral Myeloid Kinase Inhibitor Creates Synthetic Lethal Vulnerability to Venetoclax

2023 ESH Poster – Tuspetinib Oral Myeloid Kinase Inhibitor Creates Synthetic Lethal Vulnerability to Venetoclax

Oct 29, 2023
2023 ESH Poster – Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy as Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

2023 ESH Poster – Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy as Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Oct 29, 2023
Aptose Corporate Presentation September 2023

Aptose Corporate Presentation September 2023

Sep 11, 2023
Aptose Interim Clinical Update

Aptose Interim Clinical Update

Jun 10, 2023
Aptose Corporate Presentation April 2023

Aptose Corporate Presentation April 2023

Apr 13, 2023
Aptose Corporate Presentation January 2023

Aptose Corporate Presentation January 2023

Jan 6, 2023
Aptose ASH Clinical Update and Data Review

Aptose ASH Clinical Update and Data Review

Dec 11, 2022
2022 ASH Poster - A Phase 1/2 Open-label, Multicenter, Dose Escalation and Expansion Study of the Myeloid Kinase Inhibitor HM43239 (Tuspetinib) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

2022 ASH Poster - A Phase 1/2 Open-label, Multicenter, Dose Escalation and Expansion Study of the Myeloid Kinase Inhibitor HM43239 (Tuspetinib) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Dec 11, 2022
2022 ASH Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-cell Malignancies

2022 ASH Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-cell Malignancies

Dec 11, 2022
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next »
© 2023 Aptose Biosciences Inc. All Rights Reserved.
Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences